TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11001892

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) from matched related donor (MSD) and matched unrelated donor (MUD)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: No human leukocyte antigen (HLA)-matched donor
Number of subjects: 473

Group type: COMPARATOR
Intervention: With human leukocyte antigen (HLA)-matched donor
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 473
Study: 9869926

Group type: EXPERIMENTAL
Intervention: Sandimmun Neoral (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sandimmun (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (Healthy persons)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 16
Study: 1900011

Group type: EXPERIMENTAL
Intervention: rt-PA with intravenous metoprolol 15 mg acutely and then 200 mg orally daily
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo with no beta-blockade
Number of subjects: 352
Study: 6141051

Group type: EXPERIMENTAL
Intervention: Felodipine (6.25 mg to 25 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30191722

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy for insomnia (Sleep Healthy Using The Internet)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Online sleep psychoeducation (Control)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy for insomnia
Number of subjects: 87
Study: 30236079

Group type: EXPERIMENTAL
Intervention: Combined treatment plus I3C (arm 1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combined treatment plus I3C and EGCG (arm 2)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combined treatment plus I3C and EGCG plus long-term platinum-taxane chemotherapy (arm 3)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Combined treatment alone without neoadjuvant platinum-taxane chemotherapy (control arm 4)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Combined treatment alone (control arm 5)
Number of subjects: 5
Study: 27375066

Group type: EXPERIMENTAL
Intervention: Compass fundus automated perimetry (FAP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Humphrey Field Analyzer (HFA)
Number of subjects: 120
Study: 24836474

Group type: EXPERIMENTAL
Intervention: Fuji-Phycon DLT
Number of subjects: 17

Group type: COMPARATOR
Intervention: Rusch DLT
Number of subjects: 17

Group type: COMPARATOR
Intervention: Mallinckrodt DLT
Number of subjects: 17
Study: 23575054

Group type: EXPERIMENTAL
Intervention: Augmented therapy
Number of subjects: 311

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 311
Study: 19531035

Group type: EXPERIMENTAL
Intervention: Earplugs during nighttime sleep hours
Number of subjects: 88
Study: 17659942

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg/day (increased to 10 mg/day as tolerated)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 16110045

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11861267

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Number of subjects: 0
Study: 10206320

Group type: EXPERIMENTAL
Intervention: Azimilide 35 mg day(-1)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg day(-1)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Azimilide 150 mg day(-1)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Azimilide 200 mg day(-1)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg day(-1) with 3-day loading for >55 years
Number of subjects: 119
Study: 7599672

Group type: EXPERIMENTAL
Intervention: Time for a Change: A Program for Healthy Moms and Babies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 2243481

Group type: EXPERIMENTAL
Intervention: Dye red 630 nm laser
Number of subjects: 100

Group type: COMPARATOR
Intervention: Argon green 514 nm laser
Number of subjects: 100
Study: 30430

Group type: EXPERIMENTAL
Intervention: Methylphenidate, 0.5 mg/kg intravenously
Number of subjects: 0
Study: 31831574

Group type: EXPERIMENTAL
Intervention: Enhanced motivational interviewing (group intervention)
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Enhanced motivational interviewing (individual intervention)
Number of subjects: 1742

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1742
Study: 31081694

Group type: EXPERIMENTAL
Intervention: Tirasemtiv (125 mg twice daily)
Number of subjects: 744

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Tirasemtiv (tolerated dose)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Tirasemtiv
Number of subjects: 744
Study: 28941810

Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification for Hostility (IBM‐H)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Healthy Video Control (HVC)
Number of subjects: 58
Study: 26376753

Group type: EXPERIMENTAL
Intervention: Granular group (preference-setting tool)
Number of subjects: 2718

Group type: COMPARATOR
Intervention: None group
Number of subjects: 2718

Group type: EXPERIMENTAL
Intervention: All group
Number of subjects: 2718

Group type: EXPERIMENTAL
Intervention: Binary group
Number of subjects: 2718
Study: 22875659

Group type: EXPERIMENTAL
Intervention: uKIM‐1 in preterm infants with RDS and AKI
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: uKIM‐1 on day 7 in preterm infants with RDS and AKI
Number of subjects: 48
Study: 21199658

Group type: EXPERIMENTAL
Intervention: Cortisol administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20008240

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upfront or debulking regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioning regimen for ASCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance or consolidation therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term treatment with novel agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allogeneic transplantation
Number of subjects: 0
Study: 17442550

Group type: EXPERIMENTAL
Intervention: Antalgics, antipyretics, and NSAIDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NSAIDs (aspirin, ibuprofen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol (acetaminophen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personal history of atopy and mean age ≥ 8 years
Number of subjects: 0
Study: 15333723

Group type: EXPERIMENTAL
Intervention: Low-sodium, high-potassium diet (LNAHK)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: High-calcium diet (HC)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Moderate-sodium, high-potassium, high-calcium DASH-type diet (OD)
Number of subjects: 94
Study: 11772663

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) steroid plus oral placebo
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral steroid plus IM placebo
Number of subjects: 70
Study: 9833199

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outpatient therapy, drop-in center, and brokered case management
Number of subjects: 0
Study: 7641674

Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 2504593

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ofloxacin and cefotaxime
Number of subjects: 0
Study: 341901

Group type: EXPERIMENTAL
Intervention: fluocortin butylester (Vaspit) in cream, ointment, and fatty ointment
Number of subjects: 1705

Group type: COMPARATOR
Intervention: fluocortolone (Ultralan) caproate or pivalate
Number of subjects: 1705

Group type: COMPARATOR
Intervention: hydrocortisone acetate
Number of subjects: 1705
Study: 30613999

Group type: EXPERIMENTAL
Intervention: Partner present
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Mental activation (thinking about partner)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (thinking about their day)
Number of subjects: 102
Study: 28407129

Group type: EXPERIMENTAL
Intervention: Citrate-containing dialysate plus a heparin-grafted membrane (CiTED)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 25
Study: 25997827

Group type: EXPERIMENTAL
Intervention: 150 mL ropivacaine (2 mg/mL) and 0.5 mL epinephrine (1 mg/mL)
Number of subjects: 116

Group type: COMPARATOR
Intervention: 150 mL 0.9% saline (control)
Number of subjects: 116
Study: 23652169

Group type: EXPERIMENTAL
Intervention: Intraoperative colloid administration
Number of subjects: 2462

Group type: COMPARATOR
Intervention: No intraoperative colloid administration
Number of subjects: 2462
Study: 21747002

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for occlusions after OAT publication
Number of subjects: 28780

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for occlusions after guideline revisions
Number of subjects: 28780

Group type: EXPERIMENTAL
Intervention: PCI among hospitals consistently reporting diagnostic catheterizations after OAT publication
Number of subjects: 28780

Group type: EXPERIMENTAL
Intervention: PCI among hospitals consistently reporting diagnostic catheterizations after guideline revisions
Number of subjects: 28780
Study: 19095860

Group type: EXPERIMENTAL
Intervention: Anesthesiologists
Number of subjects: 61

Group type: COMPARATOR
Intervention: CRNAs
Number of subjects: 61
Study: 17111006

Group type: EXPERIMENTAL
Intervention: CHO + EAA + Glutamine (0.3 g/kg BW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHO + EAA (Control)
Number of subjects: 0
Study: 15193484

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 11388

Group type: COMPARATOR
Intervention: Natural conception (control)
Number of subjects: 11388
Study: 10657059

Group type: EXPERIMENTAL
Intervention: Sotalol, 160 mg po as loading dose
Number of subjects: 5
Study: 8773436

Group type: EXPERIMENTAL
Intervention: Aminophylline (5 mg/kg over 20 min)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 23
Study: 1835474

Group type: EXPERIMENTAL
Intervention: Vertical position (sitting or standing)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Horizontal position (side-lying or supine)
Number of subjects: 60
Study: 6295286

Group type: EXPERIMENTAL
Intervention: High-fibre diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Medium-fibre diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low-fibre diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bean diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Exercise (prescribed level)
Number of subjects: 21
Study: 31663814

Group type: EXPERIMENTAL
Intervention: Task-specific sensitivity during physical function testing
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: No pain group
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Better and unchanged groups
Number of subjects: 260
Study: 31138290

Group type: EXPERIMENTAL
Intervention: 3D display system
Number of subjects: 108

Group type: COMPARATOR
Intervention: 4K display system
Number of subjects: 108
Study: 28743247

Group type: EXPERIMENTAL
Intervention: Paclitaxel monotherapy (80 mg/m2 weekly, 3 weeks on, 1 week off)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paclitaxel plus sorafenib (400 mg orally, twice a day, starting dose of 200 mg)
Number of subjects: 60
Study: 26158573

Group type: EXPERIMENTAL
Intervention: Field grading by trained trachoma graders
Number of subjects: 269

Group type: COMPARATOR
Intervention: Photographic review by trained trachoma graders
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Consensus grade from photographic graders
Number of subjects: 269
Study: 24612097

Group type: EXPERIMENTAL
Intervention: Sarcosine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22298569

Group type: EXPERIMENTAL
Intervention: WR(+) - wheat/rye bread with in situ‐produced AXOS (180 g/d)
Number of subjects: 27

Group type: COMPARATOR
Intervention: W(‐) - refined wheat flour bread without AXOS (180 g/d)
Number of subjects: 27
Study: 20570218

Group type: EXPERIMENTAL
Intervention: Brachytherapy with (125)I seed implants, prescription dose of 145 Gy.
Number of subjects: 43

Group type: COMPARATOR
Intervention: Brachytherapy with (125)I seed implants in non-small prostate volume patients, 120 patients in total.
Number of subjects: 43
Study: 17612998

Group type: EXPERIMENTAL
Intervention: 5-week workbook-based intervention
Number of subjects: 203

Group type: COMPARATOR
Intervention: Normal care (control)
Number of subjects: 203
Study: 16230487

Group type: EXPERIMENTAL
Intervention: Stentless valve
Number of subjects: 190

Group type: COMPARATOR
Intervention: Stented valve
Number of subjects: 190
Study: 12234037

Group type: EXPERIMENTAL
Intervention: Moderate exercise (50% of peak oxygen uptake, dual-cycle ergometry)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Post-exposure rest (control group)
Number of subjects: 67
Study: 10401537

Group type: EXPERIMENTAL
Intervention: Supportive condition (Study 1)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Nonsupportive condition (Study 1)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Highly supportive condition (Study 2)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Supportive condition (Study 2)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Nonsupportive condition (Study 2)
Number of subjects: 128
Study: 7575710

Group type: EXPERIMENTAL
Intervention: DAB486IL-2
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 2688344

Group type: EXPERIMENTAL
Intervention: i.v. ranitidine (50 mg every 6 hours for 72 hours from the skin incision)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no ranitidine)
Number of subjects: 24
Study: 1112949

Group type: EXPERIMENTAL
Intervention: Intravenous propranolol (0.2 mg per kilogram)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control SGaw
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol treatment
Number of subjects: 10
Study: 31548793

Group type: EXPERIMENTAL
Intervention: Dual-task obstacle crossing (DTOC) training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Single-task obstacle crossing (STOC) training
Number of subjects: 22
Study: 29180182

Group type: EXPERIMENTAL
Intervention: Ilomedin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: High-dose oxygen
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Extended warming
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study: 26925905

Group type: EXPERIMENTAL
Intervention: Polyethylene cover
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Liposic ointment
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Artificial tear drop
Number of subjects: 96

Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 96
Study: 23500312

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 245

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy
Number of subjects: 245
Study: 21223250

Group type: EXPERIMENTAL
Intervention: Reduced chemotherapy (standard risk; SR)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Intensive chemotherapy (medium risk; MR)
Number of subjects: 171
Study: 19895208

Group type: EXPERIMENTAL
Intervention: ddI/3TC with efavirenz (EFZ)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: ddI/3TC with nevirapine (NVP)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard short-course anti-TB treatment (2EHRZ3/4RH3)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: ddI/3TC with either nevirapine or efavirenz
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: NRTI mutations
Number of subjects: 107
Study: 21325437

Group type: EXPERIMENTAL
Intervention: Dietary glycemic load (GL) for single foods
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Dietary glycemic load (GL) for mixed meals
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Carbohydrate content alone for single foods
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Carbohydrate content alone for mixed meals
Number of subjects: 134
Study: 16052108

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg over 15 min followed by 0.2 microg x kg x h infusion)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Meperidine (1 mg/kg) with midazolam (0.05 mg/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fentanyl (0.1-0.2 mg intravenous on demand)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Meperidine with midazolam
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 64
Study: 12447733

Group type: EXPERIMENTAL
Intervention: Zanamivir (10 mg inhaled once daily for 10 days)
Number of subjects: 1291

Group type: COMPARATOR
Intervention: Placebo (inhaled once daily for 10 days)
Number of subjects: 1291

Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 1291
Study: 9845131

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5FU) and cisplatin (CDDP) chemotherapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 156
Study: 8082346

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg bolus injection of alteplase over 15 min (maximum dose 50 mg)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 100 mg of alteplase over 2 h
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 53
Study: 2658856

Group type: EXPERIMENTAL
Intervention: Respiratory muscle training with a Triflow II inspirometer
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo training with a mini peak flow meter
Number of subjects: 22
Study: 4888353

Group type: EXPERIMENTAL
Intervention: Two weeks' treatment with an appropriate antibacterial drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Six weeks' treatment with an appropriate antibacterial drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 0
Study: 11486102

Group type: EXPERIMENTAL
Intervention: MMP-9
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MMP-2
Number of subjects: 39
Study: 30627826

Group type: EXPERIMENTAL
Intervention: Six bouts of exercise each separated by 48 hours
Number of subjects: 28

Group type: COMPARATOR
Intervention: Three bouts of exercise with 48 hours between the first two bouts and 8 days between the second and third bouts
Number of subjects: 28
Study: 29097272

Group type: EXPERIMENTAL
Intervention: Counselor-assisted problem-solving
Number of subjects: 132

Group type: COMPARATOR
Intervention: Internet resource comparison
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Participants with impairments
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Participants identified as impaired
Number of subjects: 132
Study: 26616256

Group type: EXPERIMENTAL
Intervention: Structured educational programme for parents
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no structured educational programme)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Corticosteroid use
Number of subjects: 134
Study: 24483841

Group type: EXPERIMENTAL
Intervention: Sickle Cell Disease (SCD) patients
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Beta Thalassemia Major (β‐TM) patients
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Beta Thalassemia Intermedia (β‐TI) patients
Number of subjects: 107

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 107
Study: 22548394

Group type: EXPERIMENTAL
Intervention: Flumetasone ointment plus 308-nm excimer laser therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: 308-nm excimer laser monotherapy
Number of subjects: 40
Study: 19793378

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of tamsulosin 0.2 mg/day and dutasteride 0.5 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg/day (alpha‐blocker group)
Number of subjects: 120
Study: 17693178

Group type: EXPERIMENTAL
Intervention: Warfarin (target international normalised ratio 2‐3)
Number of subjects: 973

Group type: COMPARATOR
Intervention: Aspirin (75 mg per day)
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 973

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 973
Study: 15165409

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic remedy (LM potency, 1/50,000 dilution)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (plain solvent)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic remedy
Number of subjects: 62
Study: 12194509

Group type: EXPERIMENTAL
Intervention: One-step protocol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Three-step protocol
Number of subjects: 10
Study: 9797360

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500-750 mg twice a day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 83
Study: 8106700

Group type: EXPERIMENTAL
Intervention: Metoprolol (titrated to a mean maximal dose of 87 mg/day)
Number of subjects: 50
Study: 2818394

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg, t.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 46963

Group type: EXPERIMENTAL
Intervention: High-fibre-containing breakfast cereal (double the normal fibre intake)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breakfast cereal containing negligible amounts of dietary fibre (control)
Number of subjects: 0
Study: 29996844

Group type: EXPERIMENTAL
Intervention: 3-day course of artemether-lumefantrine (AL)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 5-day course of artemether-lumefantrine (AL)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Both regimens (3-day and 5-day AL)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: k13 mutations
Number of subjects: 154